Clinical trial / 1976
Terminal cancer patients receiving supplemental ascorbate had a mean survival time over 4.2 times longer than similar controls.
In a clinical trial, 100 terminal cancer patients received supplemental ascorbate as part of routine management, and their progress was compared to 1,000 similar patients treated identically without supplemental ascorbate. Mean survival time was more than 4.2 times greater for ascorbate subjects (more than 210 days) than for controls (50 days). Deaths occurred for about 90% of ascorbate-treated patients at one-third the rate for controls, and the other 10% had a survival time averaging more than 20 times that of controls.
- Study type
- Clinical trial
- Who was studied
- 100 terminal cancer patients given ascorbate and 1,000 similar control patients
- What was measured
- Survival time and survival-time curves
THE PAPER
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.
Cameron E, Pauling L. Proc Natl Acad Sci U S A, 1976.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.